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Recent studies have shown that although antigens and lectins initiate the activation 
of T  cells, the proliferation of these cells is dependent on a  15,000-dalton glycoprotein 
designated T  cell growth factor (TCGF) 1 (1-9). Accordingly, two antigen-dependent 
events are essential for the realization of a competent T  cell proliferative response: the 
production of TCGF (5,  7), and the acquisition of a state of specific responsiveness to 
TCGF on the part of antigen-activated cells (10-13). As a result of this concept it has 
been proposed that there is a  unique signaling apparatus within the immune system 
designed  to  transmit  exogenous  antigenic  stimuli  to  an  endogenous,  hormonelike 
control system involving lymphokines (14,  15). 
A  number of experimental findings suggest that TCGF has characteristics similar 
to polypeptide hormones that interact with target cells by means of specific receptors. 
The mitogenic effect of TCGF is strictly concentration  dependent such that the rate 
and extent  of T  cell clonal expansion is determined by the concentration  of TCGF 
available (5,  10,  14,  15).  Moreover, the effect of TCGF appears specific for T  cells. 
TCGF promotes proliferation only of antigen- or lectin-activated T  cells and has no 
mitogenic  effect  on  unstimulated  lymphocytes, activated  B  cells,  or  cells  of other 
lineages  (10-15).  In  addition,  TCGF  activity is  absorbed only by activated T  cells 
(10-15).  The fact that  such absorption  is time, temperature, and cell concentration 
dependent, together with the finding that both viable and glutaraldehyde-fixed cells 
absorb the activity, has led us (10,  14,  15) and others (11-13)  to propose that TCGF 
interacts with activated T  cells by means of specific membrane binding sites. 
The  definitive  demonstration  of TCGF-specific binding  sites  depends  upon  the 
development of a  radiolabeled TCGF binding assay. In this report we describe such 
an  assay using  highly  purified,  internally  radiolabeled  TCGF,  and  show  that  only 
TCGF-responsive T  cells express high affinity, TCGF-specific binding sites. Moreover, 
the  characteristics  of  the  binding,  and  the  close  correlation  of the  binding  and 
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biological response  curves,  support  the  notion  that  TCGF,  in  a  manner  similar to 
polypeptide hormones,  exerts  its  effects  upon  activated  T  cells  through  a  cellular 
receptor. 
Materials  and  Methods 
Cell Cultures.  Murine TCGF-dependent cytolytic (subclone 15H)  (16) and helper (clone 18- 
33-3)  (8)  T  lymphocyte lines were  maintained as previously described at  population  levels 
between  1 ×  104 and 5 ×  105 cells/ml (doubling time ~20 h) in Iscove's Modified Dulbecco's 
Minimum Essential Medium (Iscove's DMEM;  17) supplemented with  10% heat-inactivated 
(56°C for 30 min) fetal calf serum (FCS, Sterile Systems, Inc., Logan, Utah), 50 U/ml penicillin 
G, 50/~g/ml gentamycin, and  1.0 U/ml  human  TCGF derived from JURKAT T  leukemia 
cells and  partially purified by gel  filtration  (see  following sections). All were cultured in  a 
humidified atmosphere of 5% CO2 in air at 37°C. 
All human and primate cell lines were maintained in RPMI  1640 medium  (Grand Island 
Biological Co., Grand Island, N. Y.)  supplemented with  10% FCS, 50 U/ml penicillin G, 50 
/~g/ml gentamycin, and 300/zg/ml fresh L-glutamine at population levels between 2 X  105 and 
1 X  106 cells/ml. 
Human  phytohemagglutinin  (PHA)  blasts were  prepared  by culturing peripheral blood 
lymphocytes isolated on  Ficoll-Hypaque with  I  p.g/ml  PHA  (Wellcome Reagents  Limited, 
Beckenham,  Eng.)  in  supplemented  RPMI  1640 medium  for  72  h.  Alloantigen-activated 
human blasts were prepared by co-cultivation of peripheral blood mononuclear cells from two 
individuals  (1  ×  106  cells/ml)  in  supplemented  RPMI  1640 medium  for  120  h.  Murine 
(BALB/c, The Jackson  Laboratory, Bar  Harbor,  Maine)  splenocytes and  thymocytes were 
activated with concanavalin A  (Con-A, 2.5 pg/ml, Miles Yeda, Rehovath,  Israel), Escherichia 
coli lipopolysaccharide (LPS, 20/Lg/ml, Grand Island Biological Co.), and allogeneic splenocytes 
(C57BL/6, The Jackson Laboratory) by culturing cells (2.5  X  106 cells/ml) for 48 h  (Con-A, 
LPS) or 120 h  (mixed lymphocyte culture)  in DMEM  (Grand Island Biological Co.) supple- 
mented with  10% FCS, 50 U/ml penicillin G, 50 p.g/ml gentamycin, 2-mercaptoethanol (5 x 
10  -5 M), and 300 #g/ml r-glutamine. When necessary, the proportion of blast cells was enriched 
to 90-95% by discontinuous gradient centrifugation (18). 
TCGF Assay.  TCGF biological activity was determined as previously described (5) by the 
TCGF concentration-dependent stimulation of proliferation of a  cloned murine cytotoxic T 
lymphocyte line  (CTLL-2,  subclone  15H)  (16).  CTLL  proliferation, as  indicated by  [3H]- 
thymidine (TdR) incorporation, was determined during the last 4 h of a 24-h culture period in 
the presence of serial twofold dilutions of a standard TCGF preparation and the experimental 
sample.  The  dilutions  yielding 50%  of the  maximum  CTLL  [aH]TdR  incorporation were 
determined, and that of the sample divided by that of the standard to give the concentration 
of TCGF  in  units  per  milliliter. The  standard  TCGF  preparation,  which  was  arbitrarily 
assigned a  value of 1 U/ml, routinely yielded 50% of the maximal incorporation at a dilution 
of  1:I0.  Phorbol  myristic  acetate  (PMA)  and  PHA,  which  were  used  to  induce  TCGF 
production, had negligible direct or synergistic (with TCGF) effects in the assay. 
Production and Purification of lnternally Radiolabeled TCGF.  Radiolabeled TCGF was prepared 
by stimulation of a high-producer clone (clone 6) of the human T  leukemia cell line JURKAT 
(19,  20),  in the presence of a  medium containing various radioactive amino acids. Since the 
release of TCGF from JURKAT cells was found to gradually decline with their time in culture, 
fresh aliquots of cells were thawed for each labeling experiment. The cells were grown for 3--5 
d  in culture after which they were washed with serum- and methionine-free DMEM  (MEM 
Select-Amine Kit, Grand Island Biological Co.). The cells were resuspended at 5 ×  106 cells/ml 
in  the same medium, to which was added  1.5 p.g/rnl PHA  (Wellcome Reagents),  50  ng/ml 
PMA (Consolidated Midland Corp., Brewster, N. Y,),  10 #M unlabeled methionine, and 0.5 
mCi/ml [SSS]methionine (1,100  Ci/mmol, Amersham Corp., Arlington Heights, Ilk). The cell 
supernate was harvested after incubation for  14-18 h  at  37°C, after which  1 mg/ml bovine 
serum albumin (BSA, Fraction V, Sigma Chemical Co., St. Louis, Mo.) was added as a carrier. 
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production obtained in normal, serum-free DMEM.  Exclusion of the unlabeled methionine 
resulted in extremely low levels of secreted TCGF. 
Similar conditions were used for labeling with 3H-amino acids, except that DMEM contain- 
ing the normal methionine level, 40 p.M unlabeled leucine, 65 #M unlabeled lysine, 0.5 mCi/ 
ml [SH]leucine (55 Ci/mmol, ICN, Irvine, Calif.) and 0.5 mCi/ml [SH]lysine (45 Ci/mmol) was 
substituted.  Approximately 50-60%  of the  optimal  release of TCGF  was  obtained.  Lower 
concentrations of total leucine and lysine resulted in a marked decrease in TCGF levels. 
After stimulation of JURKAT  cells in  the  presence of radioactive amino  acids, the cell 
supernate (20 ml) was'concentrated 15-fold by uhrafiltration using a YM-5 membrane (Amicon 
Corp., Lexington, Mass.). Concentrated material (>95% recovery of TCGF biological activity) 
was chromatographed at 4°C on a 1.6 × 95-cm column ofSephadex G100 Superfine (Pharmacia 
Fine Chemicals, Piscataway, N. J.) in 10 mM Tris, pH 7.5, 0.15 M  NaCI, and  100 #g/ml BSA. 
The yield of TCGF activity was ~76%. The pool of TCGF activity from the G100 column was 
equilibrated on a  YM-5 membrane with a  1/160 dilution of Pharmolyte, pH 6.5-9 (Pharmacia 
Fine Chemicals), and further fractionated by isoelectric focusing (IEF). Focusing was performed 
at 4°C on a 6 ×  180-mm cylindrical gel (7% acrylamide, 1/16 dilution of Pharmolyte, pH 6.5-9) 
at  1,000 V  for 12 h. The gel was cut into 2-mm slices and eluted (72-96 h) in 0.5 ml of 10 mM 
Tris, pH 7.5, 0.15 M NaCI, 2 mg/ml BSA. The biological activity from each slice was measured 
in the TCGF assay and 2.5 #1 was counted by liquid scintillation. A parallel gel (no sample) 
was sliced and eluted with 1 ml distilled water (4°C) for determination of a representative pH 
gradient. Radiolabeled TCGF preparations from the IEF gel were examined by sodium dodecyl 
sulfate-polyacrylamide  gel electrophoresis (SDS-PAGE) on slab gels (12% acrylamide) according 
to the methods of Ziegler et al.  (21)  and Laemmli (22)  with identical results. The gels were 
analyzed by fluorography (23). 
Unlabeled TCGF was similarly prepared by stimulation of JURKAT cells with PHA and 
PMA,  and  purified  in  the  absence of exogenous  protein  carriers by  a  combination  of gel 
filtration and IEF (9).  Such preparations contained no detectable type 1 or type 2 interferon 
activity (Frank Ruscetti, personal communication), macrophage-granulocyte colony-stimulat- 
ing activity (Frank Ruscetti, personal communication), lymphocyte-activating factor activity, 
B cell growth factor (Benjamin Sredni, personal communication), or PHA (as assessed by direct 
mitogenicity on mouse thymocytes). Unlabeled TCGF was also prepared from rat splenocytes 
by stimulation with Con A as previously described (24). 
Radiolabeled TCGF Binding Assay.  All cell types were incubated for 2 h  at 37°C  in 50 ml 
RPMI  1640, 25 mM HEPES, pH 7.2 and washed three times (50 ml) in order to remove any 
endogenous TCGF.  A  small increase in  the  level of detectable receptors was  found  for the 
TCGF-dependent murine CTLL-2, subclone  15H  cells after such  treatment. After washing, 
cells were immediately used for binding experiments or were fixed with glutaraldehyde before 
binding. Glutaraldehyde fixation was performed by suspending the cells in 2% glutaraldehyde, 
0.14 M  NaCI, and 0.05 M cacodylate buffer (pH 7.3) for 15 rain at 3°C, followed by extension 
washing (5 times) to remove glutaraldehyde (14). 
To determine the level of binding, serial dilutions of [aSS]methionine- or [SH]leucine, lysine- 
TCGF were incubated at 37°C with 0.5-2 ×  106 cells in a total volume of 200 #1 of RPMI 1640 
supplemented with 25 mM HEPES, pH 7.2, and  10 mg/ml BSA (RPMI 1640-BSA)  using 1.5 
ml  Eppendorf micro test tubes  (2236-411-1,  Brinkmann  Instruments, Westbury, N.Y.).  The 
tubes were mechanically rotated about their longest axis (horizontal position) at 20 rpm in a 
37°C water bath. After 20 or 40 min,  1 ml ice-cold RPMI  1640-BSA was added to each tube 
and  the cells were pelleted at 9,000 g  for  10 s in an  Eppendorf model 5413  centrifuge. The 
supernate was removed and counted by liquid scintillation to determine the level of unbound 
radioactivity. The cells in the pellet were resuspended with 100 #1 RPMI 1640-BSA at 0°C and 
centrifuged at 9,000 g  for 90 s through a  200-pl layer of a  mixture (25°C) of 84% silicone oil 
(550 fluid, Contour Chemical Co., North Reading, Mass.) and 16% paraffin oil (Fisher Scientific 
Co., Pittsburgh, Pa.) to remove the small amount of unbound TCGF remaining in the original 
pellet. The  tips of the tubes  (400  #1  polyethylene, Bio-Rad Laboratories, Richmond, Calif.) 
containing the cell pellet were cut-off, placed in scintillation vials, and the pellets solubilized by 
addition of 100/xl  1% SDS followed by 3 ml Biofluor (New England Nuclear, Boston, Mass.). 
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derived TCGF (purified by gel filtration or by gel filtration and IEF) to each assay tube before 
addition of the cells. The counting efficiencies for the various [aSS]methionine-TCGF  prepara- 
tions and the bound and unbound fractions after cell binding were similar (90-95%)  and no 
adjustment was made in the final results. 
The following growth factors and hormones were examined for competition with the binding 
of radiolabeled TCGF: murine epidermal growth factor (EGF), rat multiplication-stimulating 
activity (MSA), murine 2.5s nerve growth factor (NGF), and bovine fibroblast growth factor 
(FGF), all from Collaborative Research Inc., Waltham, Mass.;  murine lymphocyte-activating 
factor (LAF or interleukin 1) prepared by LPS-stimulation  of P388D1 cells (25); purified human 
leukocyte interferon type 1 (IFN-a) (a gift from Dr. Kurt Berg, University  of Aarhus, Denmark), 
human immune interferon type 2 (IFN-),)  (a gift from Dr. William Stewart, Memorial Sloan- 
Kettering Cancer Center,  New  York),  purified macrophage-granulocyte colony-stimulating 
activity (CSA)  (a gift  from  Dr.  Frank Ruscetti, National Cancer Institute, Bethesda,  Md.), 
human urinary erythropoietin (2nd international standard), and bovine-porcine insulin (Eli 
Lilly and Company, Indianapolis, Ind.). 
Radiolabeled TCGF: Time-Courses of Association and of Dissociation~Degradation.  A time-course of 
the association of [aSS]methionine-TCGF with  murine CTLL cells  (2.5 ×  106 cells/ml) was 
determined at 4 °  and 37°C using a saturating level of radiolabeled TCGF (250 pM)  in the 
absence and presence of unlabeled TCGF (25 nM). At various times, aliquots (200/tl) were 
removed and centrifuged (9,000 g  for  90  s)  through a  200-/~1 layer of 84%  silicone oil: 16% 
paraffin oil. The tips containing  the cell pellet were cut offand the samples treated as described 
for binding assay. 
The dissociation or release of intact or degraded [35S]methionine-TCGF  from murine CTLL 
cells was measured in two ways. In the first approach, a near-saturating  level of [35S]methionine- 
TCGF  (150  pM)  was  allowed to  bind to  the cells  for  60  min at  37°C.  At  that  time, the 
concentration of free  [aSS]methionine-TCGF was  reduced by a  100-fold dilution of the cell 
suspension into RPMI  1640-BSA and the culture maintained at  37°C. Aliquots of the cell 
suspension (containing 5 ×  106 cells) were removed at various time intervals and centrifuged as 
described  above  through  a  layer of silicone oil:paraffin oil  to  separate  cell-associated and 
unassociated [aSS]methionine  label. In a second approach, a similar level of [aSS]methionine- 
TCGF was allowed to bind to the CTLL cells (2.5 X 106 cells/ml) for 45 min at 4°C. At that 
time, the cells were pelleted and washed once with  1 ml RPMI  1640-BSA at 0°C to remove 
unassociated TCGF. The cells  were  resuspended at  2.5  ×  10  ° cells/ml in RPMI  1640-BSA 
containing 25 nM unlabeled TCGF and incubated at 37°C. At various times aliquots (200 ~1) 
were removed and the cells pelleted as before by centrifugation through silicone oil:paraffin oil. 
An estimate of the proportion of degraded [35S]methionine-TCGF  was made by precipitation 
of protein (4 h  at 0°C)  from aliquots of the complete cell suspension, or of washed cells, by 
adjusting each to a final concentration of 10% TCA (with  1 mg/ml BSA serving as a carrier). 
The supernate (degraded [35S]methionine-TCGF)  and precipitate (undegraded [35S]methionine- 
TCGF) were counted separately. 
Biological and Binding Responses.  A  comparison was  made between the  percentage of the 
maximum biological response (cell proliferation as measured by [aH]TdR incorporation) and 
the percentage of saturable binding of [aSS]methionine-TCGF  at various concentrations of free 
TCGF. The level of binding  was determined as described for binding  assay using murine CTLL 
cells (2.5 ×  l0  s cells/ml). The level of biological activity was determined as in a standard TCGF 
assay.  Murine CTLL cells (2 ×  104 c~ls/ml) were incubated at 37°C with quadruplicate sets 
of twofold dilutions of unlabeled TCGF in DMEM/10% FCS (200 #1 total volume). After 20 
h,  the SUlaernate from each dilution were harvested, titered in a TCGF assay,  and compared 
with a standard TCGF preparation (1 U/ml) to determine the level of remaining free TCGF. 
The original cells were pulsed with [aH]TdR for 4 h  at 37°C, and the level of radioactivity 
incorporated was used as a measure of their biological response to TCGF. 
Results 
Purification of Internally  Radiolabeled  TCGF.  TCGF released by the human T  leuke- 
mia cell  line JURKAT,  after stimulation with  PHA and PMA in the  presence of R.  ROBB,  A.  MUNCK,  AND  K.  A.  SMITH  1459 
[aSS]methionine,  was concentrated and chromatographed on a column of Sephadex 
G100 Superfine (Fig. 1A). TCGF biological activity eluted in a position corresponding 
to a  globular protein of 19-20,000 tool wt and was coincident with a small peak of 
[aSS]methionine  label. The G100 pool was further fractionated by IEF on a polyacryl- 
amide  gel using a  gradient  of pH  6.5-9.  As shown  in  Fig.  1B, the major peak of 
TCGF activity coincided with a major peak of [~S]methionine label (slices 21-23, pI 
~8.2). A secondary peak of activity (slice 38, pI ~7.9), which represented a sialylated 
form of TCGF (9), also coincided with a peak of [aSS]methionine  label. The yield of 
TCGF biological activity in  the major  IEF peak as compared  to  the original  cell 
supernate was 40%. Quantitatively and qualitatively similar results were obtained for 
fractionation of [aH]leucine, lysine-TCGF. 
When  analyzed  by one-dimensional  SDS-PAGE,  followed by fluorography,  the 
material  from the major IEF peak migrated as a single band of radiolabel at  14,800 
mol wt under nonreducing conditions and  15,500 mol wt under reducing conditions 
(Fig. 2). A single component of the same size was found by slicing a similar gel and 
recovering biological activity  (9)  and  by electrophoresis and  conventional staining 
(Coomassie Brilliant Blue R250) of unlabeled JURKAT TCGF purified by the same 
means  (Richard  Robb, unpublished observations). The similarity between the size 
estimates from  gel  filtration  and  SDS-PAGE suggests  that  a  molecule of TCGF is 
composed of a  single polypeptide chain.  Despite the relative uniformity of the size 
and  charge  characteristics  of  [~S]methionine-TCGF  from  the  major  IEF  peak, 
however, the potential for microheterogeneity requires further examination. 
The level of radioactivity in  the major IEF peak depicted in Fig.  1B was 23,600 
200- 
I  ! 
I 
E 
•  -~  L00- 
t~ 
t...) 
I--- 
A  BSAOVA  ST[  CyrC 
I:  =ii  
"  fro  ~o  ~o  ~io  ,3o 
Froction  Number 
o  olBj 
~soo-I'..  , 
=..,400  "'- 
== ,ool 
I0,000  Io0~c~ 
I0 
IOmDI  O 
OQQDm  D 
"',o,% 
-  ,5,Do0 
-,3,ooo 
•, ~ooo 
- 9,o00 
.7,o0o 
- ~ooo 
I  "... ~ooo 
30  50  70  90 
Slice  Number 
-9.0 
'8.0  :~ 
.7.0 
FIc.  1.  (A)  Elution profile of [aSS]met-radiolabeled cell supernate derived from PHA and PMA- 
stimulated JURKAT cells on a  1.6 X 95-cm column of Sephadex Gl00 Superfine. A sample (4/d) 
of every second fraction  was  used  to  determine the  level of TCGF  activity and  asS  radiolabel. 
Standards used to separately calibrate the column were BSA, ovalbumin (OVA), soybean trypsin 
inhibitor (STI), and cytochrome c (CytC). (B) IEF (pH 6.5-9) profile of material from fractions 95- 
100 of the Sephadex G100 column. A sample of each fraction was tested for the presence of TCGF 
(5 p,l) or counted to determine the level of aSS radiolabel (2.5 #l). The pH gradient was determined 
using a parallel gel (no sample). 1460  T  CELL GROWTH  FACTOR RECEPTORS 
Fro.  2.  SDS-PAGE analysis (with and without 2-mercaptoethanol [2-ME]) of [3~S]methionine- 
TCGF  (4,000 cpm) eluted from slices 21-23 of the  IEF gel  (Fig. 1B). The  radioactivity was 
visualized by fluorography. Exposure of the film for a 10-fold longer time did not reveal additional 
bands. The standards used in calibrating the gel were BSA (66,000), ovalbumin (45,000), trypsinogen 
2(24,000), Mb (I 7,800), lysozyme  (14,300), and were stained with Coomassie  Brilliant Blue R-250. 
cpm  per  unit  of  biological  activity.  By  assaying  the  protein  content  of purified 
unlabeled JURKAT  TCGF using amino acid analysis and a  dye binding assay (26), 
it was determined that a  unit of biological activity corresponds to ~8.2 ng of protein 
(Richard  Robb,  unpublished  observations).  Therefore,  the  specific  activity  of the 
[35S]methionine-TCGF was estimated to be 2,880 cpm/ng or 44,600 cpm/pmol (tool 
wt =  15,500). 
Time-Courses of Association and of Dissociation~Degradation of Radiolabeled TCGF.  The 
optimal parameters for cell binding of radiolabeled TCGF were initially determined 
using a  cloned murine, TCGF-dependent, T  cytolytic line  (CTLL-2, subclone  15H). 
Measurement  of the  time-course of association of [35S]methionine-TCGF with  these 
cells at 37°C revealed a very rapid uptake of radiolabel with maximum levels achieved 
within  15  rain  (Fig.  3A).  The  binding  was  saturable  because  in  the  presence  of 
unlabeled TCGF (25  nM),  very little [35S]methionine-TCGF was associated with the 
cells at any time point. When the incubation was conducted at 4°C instead of 37°C, 
nearly  the  same maximum level of binding  was reached,  but  only after 60  min  of 
culture  (Fig.  3A).  Similar kinetics  of association  were found  for human  PHA  blast 
cells. 
Upon a  100-fold dilution  of the CTLL cell suspension,  most of the ceil-associated 
3~S-radiolabel  (present  after  1 h  binding  at  37°C)  left the cells within  2  h  at  37°C 
(data not shown). Analysis of the released radiolabel, however, revealed that a  large 
portion  (>70%)  was no longer precipitable with  10% TCA in contrast to the nearly 
quantitative  precipitation  (>97%)  of the  original  preparation  of  [35S]methionine- 
TCGF. Thus, the radiolabeled TCGF appeared to be undergoing degradation. That 
such degradation might depend upon receptor binding was indicated by the finding 
that unlabeled TCGF (25 nM) added simultaneously with the [~SS]methionine-TCGF 
resulted in an absence of cell-associated radiolabel and a complete lack of degradation. 
Measurement  of the  rate  of conversion  of cell-associated  [35S]methionine-TCGF 
into a TCA-soluble form at 37°C revealed a half-time of 60-70 min (data not shown). 
A similar value was obtained with [3H]leucine, lysine-TCGF. Since the large number 
of leucines  and  lysines  (230)  in JURKAT-derived TCGF  (Richard  Robb,  unpub- R.  ROBB,  A.  MUNCK,  AND  K.  A.  SMITH  1461 
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Fxc;. 3.  (A) Time-course of the association of [35S]methionine-TCGF  with CTLL-2, subclone 15H 
cells in the absence (0, 37°C; m, 4°C) and presence (C), 37°C) of 25 nM unlabeled TCGF. These 
and subsequent  values for the number of TCGF binding sites per cell are based on the estimated 
specific activity of 44,600 cpm/pmol  [~S]methionine-TCGF.  As an example,  a  level of 14,000 
molecules per cell represents the binding of 520 cpm of [~S]methionine-TCGF  per 5 ×  105 CTLL 
cells. (B) Time-course of the release (Q) at 37°C of [35S]radiolabel  from CTLL cells following 45 
min binding at 4°C, removal of unassociated radiolabel, and addition of 25 nM unlabeled TCGF 
to promote  exchange. Aliquots of the whole cell suspension were removed at various times and 
adjusted to 10% TCA to determine the level of precipitable 35S radiolabel (A). 
lished observations) are likely to be distributed throughout  the molecule, the conver- 
sion of the 3H  radiolabel to a  TCA-soluble form  implies general degradation of the 
molecule rather than removal of a  small, methionine-rich section. In contrast to these 
results at 37°C, at 4°C  virtually all of the radiolabel remained TCA precipitable for 
>2 h.  Furthermore, inclusion of either ammonium  chloride (10 mM)  or chloroquine 
(100 #M), which have been shown  to inhibit lysosome-dependent hormone degrada- 
tion (27-32), resulted in >90% inhibition of the converstion of [3~S]methionine-TCGF 
to a  TCA-soluble form at 37°C, while having no effect on the level of binding. Thus, 
degradation of TCGF is temperature dependent and appears to involve internalization 
and lysosomal association. 
When binding was carried out for 45 min at 4°C to block degradation, followed by 
warming  to  37°C  and  addition of 25  nM  unlabeled  TCGF  to  promote exchange, 
about half the cell-associated label was released within 45 rain (Fig. 3B). Under these 
conditions  within  only  about  one-third  of  the  [3SS]methionine-TCGF  degraded, 
presumably because dissociation of labeled TCGF  occurred faster than  degradation. 
Thus,  association of TCGF with CTLL cells is largely reversible and is characterized 
by rapid  binding, slow  dissociation  (tl/z at  37°C  of 40-50  min),  and  receptor- and 1462  T  CELL  GROWTH  FACTOR  RECEPTORS 
lysosome-dependent degradation of the molecule. Despite the degradation, the level 
of [35S]methionine-TCGF associated with the cells (surface-bound and/or internalized, 
intact  and/or  degraded)  remained  stable  for  at  least  60  rain  at  37°C  (Fig.  3A). 
Subsequent measurements of binding capacity and receptor affinity were made after 
20 or 40 rain of culture at 37°C with little difference in the results. 
Radiolabeled TCGF Binding: Cell Type, Number of Receptors, and Affinity.  Incubation of 
increasing  concentrations  of  [Z~S]methionine-TCGF  with  antigen-specific,  TCGF- 
dependent  murine  CTLL-2  (subclone  15H)  and  HTLL  (clone  18-33-3)  cell  lines 
demonstrated  that  the binding consisted predominantly of a  saturable  component 
(Fig. 4A). Nonsaturable binding was estimated by including 25 nM unlabeled TCGF 
during the incubation. The level of binding that  remained was  linearly dependent 
upon the concentration of free [3~S]methionine-TCGF and generally constituted <4% 
of the total bound fraction in the absence of unlabeled TCGF. The average number 
of receptor sites per cell was ~ 15,000  for the CTLL and  13,000 for the HTLL (Table 
I). The sialylated form of [35S]methionine-JURKAT TCGF  (IEF slice 38,  Fig.  1B) 
and the major IEF peak of [3H]leueine, lysine-JURKAT TCGF gave similar estimates 
of the number of receptor sites for the CTLL line. In addition, glutaraldehyde-fixed 
CTLL cells bound almost as much [35S]methionine-TCGF as viable cells (Table I). 
Binding of [3~S]methionine-TCGF to murine splenocytes and thymocytes (BALB/ 
c) indicated fewer than the minimum detectable level of 60 binding sites per cell (Fig. 
4A, Table I). Upon stimulation with Con A or by alloantigen, however, a significant 
level of binding sites was  found on both splenocyte and thymocyte blasts  (Fig. 4A, 
Table I). In contrast, splenocytes stimulated with lipopolysaccharide were found to 
have  no  detectable  receptors.  These  results  are  consistent  with  those  of previous 
experiments in which only activated T  cells, but not unstimulated lymphocytes or B 
cells blasts,  absorbed TCGF biological activity (10-15).  The fact that  antigen-acti- 
vated  and  lectin-activated  cells  both  have  binding  sites  with  similar  affinities  for 
TCGF indicates that the activation step is the critical event in acquisition of TCGF 
responsiveness and that the lectin is not directly involved in the binding. 
A  Scatchard  plot of the binding of [ZSS]methionine-TCGF to the  murine CTLL 
and HTLL cell lines and Con A-activated splenocytes indicated a linear relationship 
(Fig. 4B) and a similar apparent dissociation constant  (Table I) in each case. These 
results  imply  that  a  single  set  of high-affinity binding  sites  is  responsible  for  the 
saturable binding. 
A similar analysis of binding to unstimulated human peripheral blood cells (90% 
lymphocytes) demonstrated an average of 200 binding sites per cell (Table I). Upon 
activation of the cells for 3 d with PHA or in a mixed lymphocyte reaction, the level 
of binding sites increased markedly to ~ 11,000  and 4,000 per cell, respectively (Fig. 
5A,  Table  I).  As  with  the  murine  cells,  a  linear relationship was  obtained on  the 
Scatchard plot  (Fig. 5B). The apparent affinity of the human cell-surface receptor, 
however, was three to fourfold higher than that of the murine receptor (Table I). 
A number of established human cell lines (including  10 T  cell lines, 4 B cell lines, 
2 myeioid cell lines, and a monocytoid cell line), which previous studies had shown to 
be unresponsive to TCGF (33), were found to have fewer than the detectable number 
of binding sites  for [3~S]methionine-TCGF (Table II).  In contrast, two T  cell lines 
(HUT-102B2  and  MLA-144)  known  to  produce and  respond  to TCGF  2 (34,  35), 
2 Smith, K. A., R. J.  Robb, and F. W. Ruscetti. The effect of glucocorticoids on T  cell growth factor- 
dependent leukemic cell growth. Manuscript submitted for publication. R.  ROBB,  A.  MUNCK,  AND  K.  A.  SMITH  1463 
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expressed binding sites that had apparent affinity constants similar to that of human 
PHA blast cells (Fig. 5, Table II). 
Competition for Radiolabeled  TCGF Binding.  The specificity of radiolabeled TCGF 
binding  for  murine  CTLL  cells  and  human  PHA  blast  cells  was  examined  by 
introducing a variety of growth factors and hormones as potential competitors for the 
binding.  In cases where physiological concentrations were known  (i.e.,  EGF, NGF, 
insulin, interferon, erythropoietin, LAF), the factors were used at levels above those 
known to illicit a  maximum response.  As shown in Table  III, none of the growth 
factors tested had any measurable effect on the binding of [3~S]methionine-TCGF to 
murine  CTLL  cells.  Of special  note  is  the  finding  that  LAF,  which  provides  a 
necessary signal  for TCGF  release  by T  cells  (36-38),  did  not  compete  for  [35S]- 
methionine-TCGF binding.  Moreover, human  interferon, macrophage-granulocyte 
CSA,  insulin,  and  erythropoietin also  failed  to  exert  a  significant effect on  [aSS]- 
methionine-TCGF binding to human PHA blast cells. 
Competition for [35S]methionine-TCGF binding was also examined using different 
preparations  of TCGF.  As  shown  in  Table  III,  unlabeled  TCGF  derived  from 
JURKAT cells (purified through IEF and/or gel filtration) almost completely abro- 
gated [35S]methionine-TCGF binding to both murine CTLL cells and human PHA 1464  T  CELL GROWTH  FACTOR  RECEPTORS 
TABLE  I 
Characteristics of [asS] Methionine-TCGF Binding  to  Unstimulated  and Stimulated  Ceils 
Cell type  Stimulant  [a'~S]Methionine-TCGF  binding* 
Sites~cell  Dissociation 
constant 
(X  10 -'2 M) 
Murine cells 
Splenocytes  -  <60  - 
Thymocytes  -  <60  - 
Splenocytes  Con A  9,000 ± 340  19.6 +  1.1 
Splenocytes  Alloantigen  5,800 + 400  24.6 _-. 4.1 
Thymocytes  Con A  3,180 ± 310  19.1 ±  1.5 
Splenocytes  LPS  <60  - 
CTI,L-2, subclone 15H  --  14,800 ±  1,900  20.4 ± 0.8 
CTLL-2, subclone 15H  -  13,200  - 
(glutaraldehyde-fixed) 
HTLL, clone 18-33-3  -  12,700 ± 2,300  20.1 ±  1.6 
Human cells 
Peripheral blood mononuclear cells  -  210  7.4 
Peripheral blood mononuclear cells  PHA  10,900 ± 240  5.4 +  1.1 
Peripheral blood mononuclear cells  Alloantigen  4,300 ± 340  4.9 + 0.4 
* The calculated values of the number of binding sites per cell and the dissociation constant are based on 
35,  i  the estimated specific activity of 44,600 cpm/pmol [  S]meth onine-TCGF and represent the mean and 
SEM of two or more determinations. 
blast  cells.  Although JURKAT-derived  TCGF  migrates as  a  single  major  peak  on 
IEF  (pI  8.2),  TCGF  derived from  normal  human  tonsil cells is heterogeneous  with 
respect  to  charge,  separating  into  three  distinct  forms  (pI  8.2,  7.9,  and  7.6)  (9). 
Previous  studies  revealed that  this  heterogeneity  is  due  to  variable sialylation and 
glycosylation, and  that  the  carbohydrate  component  is  not  essential  for  biological 
activity (9). It was of interest, therefore, to determine the relative competitive efficiency 
of each  of the  three  species of tonsil-derived TCGF  isolated  from  IEF  gels  in  the 
[a~S]methionine-TCGF binding assay. When present at 2 nM TCGF, each of the three 
IEF fractions was capable of almost completely inhibiting [3~S]methionine-JURKAT 
TCGF  binding to CTLL cells (Table III). Furthermore, when compared on the basis 
of biological activity (TCGF cell-proliferation assay), very similar concentrations of 
unlabeled JURKAT  TCGF and of the three tonsil-derived IEF fractions were needed 
to reduce the binding of [35S]methionine-TCGF by 50% (data not shown). The finding 
that  tonsil-derived  material  of  three  distinct  isoelectric  points  competed  for 
[3~S]methionine-TCGF  binding  relative  to  its  respective  TCGF  biological  activity 
supports the impression that the substance responsible for the competition, as well as 
the binding, is TCGF, and not a  contaminant in the JURKAT-derived  preparations 
(both radiolabeled and unlabeled). 
The concentration  dependence of the competition of unlabeled TCGF  with  [3~S]- 
methionine-TCGF binding is shown  in  Fig. 6.  Unlabeled JURKAT-derived  TCGF 
competed for [35S]methionine-TCGF binding to both murine CTLL cells and human 
PHA blast cells with  nearly superimposable curves. The concentration  of unlabeled 
TCGF  leading  to  50%  competition  was  0.068  U/0.2  ml,  nearly  the  same  as  the 
concentration of [aSS]methionine-TCGF (0.066 U/0.2 ml) used in the reaction mixture. 
Since  at  this  level  of radiolabeled TCGF  (175  pM)  the  binding  was  at  saturation R.  ROBB,  A.  MUNCK,  AND  K.  A.  SMITH  1465 
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(Figs.  4A  and  5A),  addition  of an  equal  amount  of unlabeled  TCGF  would  be 
expected to give ~50% competition. 
In comparison to unlabeled human TCGF, TCGF derived from Con A-activated 
rat  splenocytes  was  approximately  six-fold  less  effective in  competing  with  [35S]- 
methionine-TCGF for binding to murine CTLL cells (50% competition occurred at 
0.4 U/0.2 ml) (Fig. 6). This result could mean that human TCGF has a higher affinity 
for the murine cell binding site than does rag TCGF. Of particular note with regard 
to the correlation of [~S]methionine-TCGF binding and biological activity was the 
finding  that  although  rat  TCGF  competed  for  [3SS]methionine-TCGF binding  to 
murine cells, there was no competition by rat TCGF for binding to human PHA blast 
cells (Fig. 6). This result corresponds to our prior findings on the species restriction of 
TCGF; i.e., that rat TCGF has mitogenic activity for murine cells but not for human 
cells (5). 
Comparison of TCGF Biological Activity  and Radiolabeled TCGF Binding.  In  assessing 
the biological relevan~ze of the binding demonstrated for radiolabeled TCGF, it was 
of particular interest to compare the concentrations of TCGF that result in significant 
binding with those responsible for in vitro proliferation. Seria~l two-fold dilutions of 
unlabeled JURKAT  TCGF  were  incubated  with  the  murine  CTLL  line  as  in  a 
standard TCGF assay. After 20 h of culture, the supernates were harvested and placed 1466  T  CELL GROWTH FACTOR  RECEPTORS 
TABLE  II 
Characteristics of [asS]Methionine-TCGF Binding of Cell Lines 
Cell line  Cell type 
[35S]Methionine-TCGF  binding* 
Dissociation con-  Sites/cell  stant (× 10  -12 M) 
CCRF-CEM  T  <60  - 
HPB-MLT  T  <60  - 
HSB-2  T  <60  - 
JM  T  <60  - 
JURKAT (clone 6)  T  <60  - 
MOLT-3  T  <60  - 
MOLT-4  T  <60  - 
PEER  T  <60  - 
RPMI 8402  T  <60  - 
T-ALL-  1  T  <60  - 
HUT-102B2  T  13,000 +  1,900  6.0 •  0.6 
DAUDI  B  <60 
RM- 1  B  <60 
RPMI 1788  B  <60 
RAJI  B  <60 
K-562  Myeloid  <60  - 
HL-60  Promyelocyte  <60  - 
U-937  Monocytoid  <60  - 
MLA-144 (clone 15)  Primate T cell  8,200 :t: 2,100  8.0 :t: 0.2 
* Values represent the mean and SEM of two or more determinations. 
into a  second TCGF assay to  measure the concentration of TCGF remaining after 
exposure to the cells. The cells from which the supernates were taken were then pulsed 
with [3H]TdR to measure their response to the original exposure to TCGF. When the 
data resulting from the [3H]TdR incorporation of the original cells were compared to 
the concentration of free TCGF remaining after the incubation, it was clear that, over 
a  wide range, the rate of CTLL [aH]TdR incorporation was logarithmically related 
to  the  concentration  of  free  TCGF.  When  the  data  from  this  experiment  were 
compared to the binding curve for [3~S]methionine-TCGF  to CTLL cells (Fig. 7), the 
concentration of TCGF  that  stimulated a  given fraction of the  maximum CTLL 
proliferation was remarkably similar to" the concentration that  resulted in the same 
fraction  of occupied  receptor  sites.  For  example,  the  concentration of TCGF  that 
promoted  half-maximal  [aH]TdR  incorporation was  0.03  U/ml  (16  pM)  and  the 
concentration of [aSS]methionine-TCGF giving half-maximal binding was 0.04 U/ml 
(21  pM). Moreover, the maximum biological response occurred at a concentration of 
TCGF  that  corresponded  to  ~90%  saturation of the  binding sites.  The  similarity 
between the biological dose-response curve and the  [3~S]methionine-TCGF binding 
curve  indicates  that  the  biological  response  is  nearly proportional  to  the  TCGF- 
binding site occupancy. 
Discussion 
The restriction of radiolabeled TCGF binding to TCGF-responsive cells, the lack 
of competition by other growth factors and hormones, the high affinity of the binding, R.  ROBB, A.  MUNCK,  AND  K.  A.  SMITH 
TABLE III 
Competition for [asS]Methionine- TCGF Binding* 
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Potential competitors  Concentration 
Target cells 
Murine CTLL cells  Human PHA blast cells 
sites~cell 
Control  -  14,000 ± 340 
EGF  2 #M  14,000 ±  1,100 
NGF (2.5 s)  0.5 #M  14,100  ± 340 
MSA  1 ~tM  14,000 ± 200 
FGF  1 #M  13,600 ± 60 
LAF  60  U/ml  14,000  ± 340 
IFN-a  40,000 U/ml 
IFN-y  40,000 U/ml 
CSA 
Erythropoietin  5 U/ml 
Insulin (bovine-porcine)  10  U/ml 
TCGF (JURKAT)  2 nM  150 ± 80 
TCGF (tonsil, IEF pI 8.2)  2 nM  110 ± 30 
TCGF (tonsil, IEF pI 7.9)  2 nM  140 + 20 
TCGF (tonsil, IEF pI 7.6)  2 nM  180 ± 70 
%  inhibi- 
lion 
0 
0 
0 
0 
3 
0 
99 
99 
99 
99 
sites~cell  %  inhibi- 
lio?l 
10,300 ± 340  0 
10,000 + 760  3 
10,800 ± 60  0 
10,100 ± 410  2 
10,400 ± 680  0 
10,200 ± 800  1 
80 ± 20  99 
* The assays were performed with [3SS]methionine-TCGF  at a near-saturating concentration (~120 pM 
free TCGF for the murine CTLL and 75 pM free TCGF for the human PHA blasts). Values represent 
the mean and SEM of two determinations. 
and the close correlation between the concentrations of TCGF that bind to ceils and 
those that  mediate the T  cell proliferative response, all support the conclusion that 
the  binding site  detected  in  these  studies  is  on  the  receptor  through  which  the 
biological effects of TCGF are initiated. The implication of these findings is that, for 
the first time, it will be possible to apply a quantitative approach to physiological and 
pathophysiological  studies  of  an  immunologically important  lymphokine  and  its 
receptor. 
The lack of detectable TCGF binding sites on unstimulated murine lymphocytes, 
as  well  the  presence  of very  few  binding sites  on  unstimulated human peripheral 
blood  lymphocytes,  stands  in  contrast  to  the  easily  detectable  levels  found  on 
alloantigen- and lectin-activated murine and human cells. These results provide an 
explanation  for  the  observation  that  highly  purified,  lectin-free  TCGF  does  not 
promote detectable mitosis of unstimulated lymphocytes, whereas TCGF initiates and 
maintains the proliferation of T  cells once activated by antigen or lectin (10-15). The 
low level of binding  sites found on unstimulated human peripheral blood lymphocytes 
(200 sites/cell)  is just above the detection limit of the assay and represents only 30 
cpm bound/2 ×  106 cells. Since the assay yields only an average level of binding in 
the whole cell population, the value of 200 sites/cell could represent a  low level of 
receptor sites on most or all of the cells, or a  high level of sites on a  small fraction 
(<2%) of activated cells within the population. If this latter possibility were true, then 
the determination of the level of TCGF receptor sites in various disease states could 
yield information as to the proportion of circulating, activated T  cells. 
The  increase  in  the  level  of  receptor  sites  found  upon  alloantigen and  lectin 
stimulation  (>50-200-fold)  mirrors  earlier  studies  by  ourselves  and  others  where 1468  T  CELL  GROWTH  FACTOR  RECEPTORS 
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absorption of biological activity was found to be restricted to activated cells (10-13). 
The  magnitude  of the  rise  in  receptor  number  after  activation  cannot  be  solely 
attributed to an increase in cell surface area as a result of blastogenesis (based on cell 
volume determinations,  the surface area increased only 4-8-fold). Rather,  the data 
support an actual increase in the average surface density of receptor sites.  In addition, 
the lack of detectable [~SS]methionine-TCGF binding to LPS-activated B cell blasts, 
which were the same size as the lectin-activated blasts, not only lends support to this 
conclusion but also confirms that the high affinity of TCGF for activated lymphocytes 
is restricted to T  cell blasts. 
In addition to lectin- and antigen-activated cells, cloned, antigen-specific cytolytic 
and helper TCGF-dependent murine T  cell lines also expressed significant numbers 
of receptor sites.  In  contrast to most  human  T  cells cultured  in TCGF-containing 
medium, which often require periodic restimulation with antigen to maintain respon- 
siveness to TCGF  (39), these murine lines have retained their sensitivity to TCGF, 
without  restimulation,  for several years in culture  (3, 8).  Moreover, the number of 
receptor sites detected on these cells has fluctuated <20% over a 6-too period. Together 
with the data on antigen- and lectin-activated cells, these findings emphasize that the 
appearance and persistence of TCGF-speciflc binding sites are critical parameters for 
T  cell clonal expansion. 
The lack of receptor sites on all of the non-T cell, and most of the neoplastic T  cell 
lines thus far examined, is consistent with their apparent lack of TCGF responsiveness. 
Presumably, these cell lines are either fixed in an autonomous proliferative cycle or 
respond to an  as yet unidentified endogenous "growth" factor. The human  HUT- 
I02B2  and  gibbon  ape  MLA-144  cell lines,  however, did  manifest  an  appreciable 
number of receptor sites that bound [3SS]methionine-TCGF with an affinity similar 
to that found for activated human T  cell blasts. In recent studies, these two cell lines 
have been shown to be unique, since they appear to both produce and  respond to 
TCGF.  Although  the  HUT-102B2  cells  release  barely  detectable  levels  of TCGF 
activity into the culture medium, TCGF-Iike activity is easily demonstrable on the 
cell surface as shown by acid-glycine elution (35). Furthermore, HUT-102B2 cells are 
responsive to TCGF, since unlike other cell lines tested, exogenous supplementation 
with TCGF enhances  their growth  rates  (35).  The MLA-144 cell line is somewhat 
different in that TCGF activity is easily detectable in the culture medium (34). That 
MLA-144 cells are TCGF-responsive was recently shown through studies employing 
glucocorticoids.  2 As has been shown for normal T cells (40, 41), glueocorticoids inhibit 
TCGF  production by MLA-144  cells  and  also  suppress  their rate of proliferation. 
TCGF supplementation counteracts this effect in a concentration-dependent fashion. 
The restriction of the binding of radiolabeled TCGF to T  cell blasts and TCGF- 
dependent T  cell lines, together with the finding that TCGF selects only for T  cell 
growth (10-15), suggests that TCGF does not directly interact with B cells.  Although 
TCGF was  the prototype lymphokine for the class of biologically active molecules 
designated interleukin 2, subsequent observations of B cell proliferation or maturation 
that have been attributed to this class of molecules (42, 43) should be interpreted with 
caution. Such B cell responses could well be due to the effect of TCGF on residual T 
cells in the T-depleted cell populations used in the experiments or to components of 
the interleukin 2 preparations other than TCGF. In this regard, the purification of 
TCGF from JURKAT leukemia cells may have been aided due to the fact that these 1470  T CELL GROWTH FACTOR RECEPTORS 
cells,  in  contrast  to  a  heterogenous  normal  mononuclear cell  population,  do  not 
produce detectable quantities of several other biologically active moieties (e.g., CSA, 
B cell-stimulating factor(s), LAF) upon lectin stimulation. 
The absolute values for the dissociation constant and number of binding sites per 
cell are dependent upon preliminary estimates of the purity and the specific activity 
of the radiolabeled TCGF preparations. While the JURKAT-derived [35S]methionine- 
TCGF  was  reasonably  uniform  with  respect  to  pI  and  to  size  on  SDS-PAGE,  a 
definitive demonstration of homogeneity requires further examination. In this regard, 
however, since material from each of the three distinct IEF peaks of tonsilar TCGF 
competed almost equally with JURKAT-derived [35S]methionine-TCGF binding, it 
seems highly unlikely that a significant portion of the bound radiolabel could represent 
a copurifying contaminant. In addition, at the lowest concentrations of [3~S]methio- 
nine-TCGF tested on human PHA blasts, as much as 80-85% of the total radiolabel 
was  in  the  bound  fraction,  suggesting  that  this  is  a  minimum  estimate  of  the 
proportion of TCGF in the preparation. The specific activity used in the calculations 
was based on a  preliminary estimate of the relationship between biological activity 
and protein mass. The latter value is dependent on the purity of the unlabeled TCGF 
preparations and the accuracy of the biological and protein assays. Any error would 
result in a systematic shift in the receptor number and dissociation constant. Never- 
theless, while the absolute values presented in this report may be somewhat in error, 
the relative abundance and apparent  affinities of the receptor sites on the different 
types of stimulated and unstimulated cells, and the conclusions based on those relative 
values are unlikely to be affected. 
The seeming linearity of the data when analyzed by Scatchard plots is consistent 
with  all  of the  receptor sites  on  a  given cell  type having approximately the same 
affinity for TCGF. The dissociation constant is only an apparent one, however, since 
processes of internalization and/or degradation may be taking place during the time 
used to measure binding.  If significant amounts of degraded  [35S]methionine TCGF 
were released from the cell, then the value of free TCGF assumed  to correspond to 
equilibrium conditions would have been overestimated. Nevertheless, the data indi- 
cate, within experimental error, that receptor sites on murine Con-A and alloantigen- 
activated blasts and long-term T  helper and cytolytic cell lines all have roughly the 
same apparent affinity. Similarly, the receptor sites on human PHA and alloantigen- 
activated blasts and  HUT-102B2 cells also appear to have approximately the same 
affinity. The affinity of the receptor sites of the human and gibbon ape cells (MLA- 
144), however, were significantly higher than those of murine cells for human TCGF. 
The binding of radiolabeled TCGF to murine and human cells was similar in many 
respects to the binding of other polypeptide hormones and factors to their target cells. 
Like  insulin  (44)  and  EGF  (29),  the  binding  was  rapid  and  largely  reversible. 
Moreover, the binding sites appeared to be on the cell surface because glutaraldehyde- 
fixed  cells  bound  nearly  as  much  [3~S]methionine-TCGF  as  viable  cells  and  the 
majority of TCGF biological activity could be eluted after absorption to such  fixed 
cells  (14).  As  in  the case of several other polypeptide factors  (28-32),  radiolabeled 
TCGF underwent degradation that was time, temperature, and receptor dependent. 
In addition, as with insulin (32), EGF (28, 29), and human growth hormone (30, 31), 
degradation  was  blocked  by  the  lysosomotropic agents,  ammonium  chloride  and 
chloroquine.  By  analogy  to  these  and  other  polypeptide factors  (45),  the  cellular R.  ROBB,  A.  MUNCK,  AND  K.  A.  SMITH  1471 
degradation  of TCGF  can  be  expected  to  involve  internalization  by  adsorptive 
pinocytosis and lysosomal association. 
Besides serving as a means of detecting cellular receptors, the binding assay can be 
used as  in  Fig.  6  as a  competitive assay for unlabeled TCGF.  Compared with  the 
biological assay of proliferation, the competitive assay is faster (1 vs. 24 h  for murine 
CTLL or 48 h for human target cells)  and should avoid some of the complications of 
nonspecific inhibitors  of cell division  and  metabolism  that  affect the  proliferation 
assay. Moreover, increasing the specific activity of the radiolabeled TCGF by increas- 
ing  the  ratio  of labeled  to  unlabeled  amino  acids  in  the  original  culture  or  by 
improving the efficiency of their incorporation, should enhance the sensitivity of the 
competitive assay  (about  0.3  U  TCGF/ml)  by allowing  the  use of a  lower molar 
concentration of radiolabeled TCGF. In this regard, attempts to prepare high specific 
activity,  radioiodinated  TCGF  have  thus  far  met  with  disappointing  results  (Dr. 
Richard Robb, unpublished observations). A significant portion of the TCGF biolog- 
ical  activity was  consistently lost  during  the  labeling process,  a  fact  which  would 
complicate evaluation of the subsequent binding data. Internally radiolabeled TCGF 
has an advantage in that the radiolabeled molecules behave identically with unlabeled 
molecules  in  associating  with  the  celluar  receptor  (as  determined  by substituting 
various amounts of unlabeled TCGF for [35S]methionine-TCGF during the binding 
assay).  In  addition,  the  ~S-,  and  especially the  3H-,  substituted  molecules have  a 
much longer half-life than iodinated preparations. 
The  biological  relevance of the  TCGF  receptor sites  described  in  this  report  is 
emphasized by the close correlation between the concentrations of TCGF giving rise 
to a proliferative response (16 pM free TCGF mediated half-maximal proliferation of 
TCGF-dependent CTLL cells) and the concentrations leading to significant occupa- 
tion of receptor sites (21 pM free [~SS]methionine-TCGF led to half-maximal binding). 
This finding provides an explanation for the strict TCGF concentration-dependence 
of T  cell proliferation that serves as the quantitative basis for the biological TCGF 
assay. Moreover, because TCGF appears to be degraded once TCGF-receptor binding 
occurs, it  necessarily follows that  the dynamics of TCGF-receptor turnover in  part 
determines the concentration of TCGF available to proliferating T  cells. As a  result 
of these findings, it may be anticipated that the extent of in vitro, and most probably 
in vivo, T  cell clonal expansion after lectin or antigen activation is determined by the 
TCGF concentration, the acquisition and persistence of TCGF-specific receptors, the 
affinity of the  receptors  for TCGF,  and  the  rate  of degradation  of TCGF and  its 
receptor.  It  appears,  therefore, that  an  endocrinological approach  to  the  study  of 
TCGF and its receptor will provide not only new insight  important for the in vitro 
cultivation of T  cells,  but  possibly new  diagnostic  and  therapeutic approaches  for 
dealing with disorders that involve T  cells. 
Summary 
To examine directly the hypothesis that T cell growth factor (TCGF) interacts with 
target cells in a fashion similar to polypeptide hormones, the binding of radiolabeled 
TCGF to various cell populations was investigated. The results indicate that TCGF 
interacts with activated T  cells via a  receptor through which it initiates the T  cell 
proliferative response. 
Internally radiolabeled TCGF, prepared from a  human T  leukemia cell line and 1472  T  CELL GROWTH  FACTOR RECEPTORS 
purified by gel filtration and isoelectric focusing, retained biological activity and was 
uniform  with  respect  to size and  charge.  Binding of radiolabeled  TCGF  to TCGF- 
dependent  cytolytic T  cells occurred rapidly  (within  15 rain  at  37°C)  and was both 
saturable  and  largely  reversible.  In  addition,  at  37°C,  a  receptor-  and  lysosome- 
dependent degradation of TCGF occurred. Radiolabeled TCGF binding was specific 
for activated, TCGF-responsive T  cells. Whereas unstimulated lymphocytes of human 
or murine origin and  lipopolysaccharide-activated  B  cell blasts expressed  few if any 
detectable  binding  sites,  lectin-  or alloantigen-activated  cells  had  easily  detectable 
binding sites.  Moreover, compared with lectin- or alloantigen-activated T  cells, long- 
term  TCGF-dependent  cytolytic and  helper T  cell  lines  and TCGF-dependent  neo- 
plastic T  cell lines bound TCGF with a similar affinity (dissociation constant of 5-25 
pM)  and  expressed  a  similar  number  of receptor  sites  per  cell  (5,000-15,000).  In 
contrast, a number of TCGF-independent cell lines of T  cell, B cell, or myeloid origin 
did  not  bind  detectable  quantities  of radiolabeled  TCGF.  Binding  of radiolabeled 
TCGF  to TCGF-responsive  cells  was specific,  in  that  among several  growth  factors 
and  polypeptide  hormones  tested,  only  TCGF  competed  for  binding.  Finally,  the 
relative magnitude of T  cell proliferation induced by a  given concentration of TCGF 
closely paralleled the fraction of occupied receptor sites. As the extent of T  cell clonal 
expansion  depends  on  TCGF  and  on  the  TCGF  receptor,  the  dissection  of the 
molecular  events  surrounding  the  interaction  of TCGF  and  its  receptor  that  these 
studies  permit,  should  provide  new  insight  into  the  hormonelike  regulation  of the 
immune response by this lymphokine. 
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